SCHEMBL9040913

SCHEMBL9040913

CCC(=O)c1ccc(F)cc1N

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 1/20 0.47
HSP90AB1 P08238 1/20 0.46
CES2 O00748 2/20 0.42
CES1 P23141 2/20 0.42
HDAC1 Q13547 4/20 0.41
KCNH2 Q12809 1/20 0.40
POLB P06746 1/20 0.39
ALDH1A1 P00352 3/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
CHRNA7 P36544 1/20 0.39
HTT P42858 2/20 0.37
KDM4E B2RXH2 1/20 0.37
LMNA P02545 1/20 0.37
TP53 P04637 1/20 0.37
MAPT P10636 1/20 0.37
ALOX15 P16050 1/20 0.37
MAPK1 P28482 1/20 0.37
HSD17B10 Q99714 1/20 0.37
HDAC3 O15379 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30000930 0.85 KEAP1 (0.61) KEAP1HSP90AB1CES2CES1HDAC1
SCHEMBL9042482 0.85 KEAP1 (0.61) KEAP1HSP90AB1CES2CES1HDAC1
SCHEMBL27486497 0.83 KEAP1 (0.48) KEAP1CES2CES1HDAC1KCNH2
Hydrochloric Acid SCHEMBL4050944 0.81 KEAP1 (0.47) KEAP1CES2CES1HDAC1POLB
SCHEMBL196379 0.81 CES2 (0.61) HSP90AB1CES2CES1KCNH2L3MBTL1
SCHEMBL29746067 0.81 CES2 (0.61) HSP90AB1CES2CES1KCNH2L3MBTL1
SCHEMBL9559750 0.81 HSP90AB1 (0.48) HSP90AB1KCNH2POLBALDH1A1HTT
SCHEMBL1341319 0.81 KEAP1 (0.43) KEAP1CES2CES1HDAC1POLB
SCHEMBL12780437 0.79 HSP90AB1 (0.47) HSP90AB1CES2CES1KCNH2POLB
SCHEMBL9043077 0.79 HSP90AB1 (0.47) HSP90AB1POLBALDH1A1SMN1; SMN2L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101228142-A Intermediate compounds for the synthesis of pharmaceutical preparations, and process for their preparation MITSUBISHI TANABE PHARMA CORP (JP) 2008-07-23 CN claimed
US-20220162209-A1 SALICYL-ADENOSINEMONOSULFAMATE ANALOGS AND USES THEREOF MEMORIAL SLOAN-KETTERING CANCER CENTER (US) 2022-05-26 US disclosed
CN-105073751-B The substituted imidazoles new as Casein kinase 1 δ/epsilon inhibitor 百时美施贵宝公司 2018-11-30 CN disclosed
CN-107820492-A Pyridin-3-yl acetic acid derivatives as inhibitors of HIV replication VIIV保健英国第五有限公司 2018-03-20 CN disclosed
CN-105189511-B Inhibitors of human immunodeficiency virus replication 百时美施贵宝公司 2017-05-24 CN disclosed
CN-105189511-A Inhibitors of human immunodeficiency virus replication BRISTOL MYERS SQUIBB CO 2015-12-23 CN disclosed
CN-105073751-A Novel substituted imidazoles as casein kinase 1 [delta]/[epsilon] inhibitors BRISTOL MYERS SQUIBB CO 2015-11-18 CN disclosed
CN-102348692-A Substituted 2-mercaptoquinoline-3-carboxamides as kcnq2/3 modulators GRUENENTHAL GMBH 2012-02-08 CN disclosed
CN-102120741-A Production method of an optically active compound MITSUBISHI TANABE PHARMA CORP 2011-07-13 CN disclosed
CN-102050820-A Preparation method of compound with optical activity MITSUBISHI TANABE PHARMA CORP 2011-05-11 CN disclosed
CN-101228142-A Intermediate compounds for the synthesis of pharmaceutical preparations, and process for their preparation MITSUBISHI TANABE PHARMA CORP (JP) 2008-07-23 CN disclosed
EP-0471358-B1 Fluoroethylcamptothecin derivatives KYORIN SEIYAKU KK (JP) 1996-05-08 EP disclosed
EP-0325247-B1 CAMPTOTHECIN DERIVATIVES AND PROCESS FOR PREPARING SAME KABUSHIKI KAISHA YAKULT HONSHA (JP) 1993-05-19 EP disclosed
EP-0471358-A1 Fluoroethylcamptothecin derivatives KYORIN PHARMACEUTICAL CO., LTD. (JP) 1992-02-19 EP disclosed
US-5061800-A ANTITUMOR AGENTS KABUSHIKI KAISHA YAKULT HONSHA (JP) 1991-10-29 US disclosed
EP-0325247-A1 Camptothecin derivatives and process for preparing same KABUSHIKI KAISHA YAKULT HONSHA (JP) 1989-07-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220162209-A1 SALICYL-ADENOSINEMONOSULFAMATE ANALOGS AND USES THEREOF ADSL, SLC35B2, ADORA1 KEAP1 988/4885HSP90AB1 1395/4885CES2 2295/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.